A patent review of butyrylcholinesterase inhibitors and reactivators 2010–2017

References

• Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res. 2004;50:433–440.
   PubMed Web of Science ®Google Scholar
• Colovic MB, Krstic DZ, Lazarevic-Pasti TD, et al. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol. 2013;11:315–335.
   PubMed Web of Science ®Google Scholar
• Yang Y, Aloysius H, Inoyama D, et al. Enzyme-mediated hydrolytic activation of prodrugs. Acta Pharm Sin B. 2011;1:143–159.
   Google Scholar
• Mesulam M, Guillozet A, Shaw P, et al. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis. 2002;9:88–93.
   PubMed Web of Science ®Google Scholar
• Nordberg A, Ballard C, Bullock R, et al. A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer’s disease. Prim Care Companion CNS Disord. 2013;15:1–23.
   Google Scholar
• Kunal R. Quantitative structure-activity relationships in drug design, predictive toxicology, and risk assessment:IGI Glob, 2015.
   Google Scholar
• Nicolet Y, Lockridge O, Masson P, et al. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem. 2003;278:41141–41147.
   PubMed Web of Science ®Google Scholar
• Chen X, Fang L, Liu J, et al. Reaction pathway and free energy profile for butyrylcholinesterase-catalyzed hydrolysis of acetylcholine. J Phys Chem B. 2011;115:1315–1322.
   PubMed Web of Science ®Google Scholar
• Brian BJ, Lau EY, Fattebert JL, et al. Modeling the binding of CWSA to AChE and BuChE. Mil Med Sci Lett (Voj Zdr List. 2013;82:1–13.
   Google Scholar
• Macdonald IR, Martin E, Rosenberry TL, et al. Probing the peripheral site of human butyrylcholinesterase. Biochemistry. 2012;51:7046–7053.
   PubMed Web of Science ®Google Scholar
• Scheltens P, Blennow K, Breteler MMB, et al. Alzheimer’s disease. Lancet. 2016;388:505–517.
   PubMed Web of Science ®Google Scholar
• Unzeta M, Esteban G, Bolea I, et al. Multi-target directed donepezil-like ligands for Alzheimer’s disease. Front Neurosci. 2016;10:1–24.
   PubMed Web of Science ®Google Scholar
• Serrano-Pozo A, Frosch MP, Masliah E, et al. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189.
   PubMed Web of Science ®Google Scholar
• Perry G, Cash AD, Smith MA. Alzheimer disease and oxidative stress. J Biomed Biotechnol. 2002;2:120–123.
   PubMedGoogle Scholar
• Greenough MA, Camakaris J, Bush AI. Metal dyshomeostasis and oxidative stress in Alzheimer’s disease. Neurochem Int. 2013;62:540–555.
   PubMed Web of Science ®Google Scholar
• Myhre O, Utkilen H, Duale N, et al. Metal dyshomeostasis and inflammation in Alzheimer’s and Parkinson’s diseases: possible impact of environmental exposures. Oxid Med Cell Longev. 2013;2013:726954.
   PubMedGoogle Scholar
• Perry E, McKeith I, Ballard C. Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology. 2003;60:1852–1853.
   PubMed Web of Science ®Google Scholar
• Das UN. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med Sci Monit. 2007;13:RA214–21.
   PubMed Web of Science ®Google Scholar
• Diamant S, Podoly E, Friedler A, et al. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci. 2006;103:8628–8633.
   PubMed Web of Science ®Google Scholar
• Reid GA, Darvesh S. Butyrylcholinesterase-knockout reduces brain deposition of fibrillar β-amyloid in an Alzheimer mouse model. Neuroscience. 2015;298:424–435.
   PubMed Web of Science ®Google Scholar
• Bartus R, Dean R, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408–414.
   PubMed Web of Science ®Google Scholar
• FDA-approved treatments for Alzheimer’s. Available from: https://www.alz.org/dementia/downloads/topicsheet_treatments.pdf. [Last access Mar, 4 2018]
   Google Scholar
• Grossberg GT. Cholinesterase inhibitors for the treatment of Alzheimer’s disease: getting on and staying on. Curr Ther Res Clin Exp. 2003;64:216–235.
   PubMed Web of Science ®Google Scholar
• Greig N, Yu QS, Brossi A et al. Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of Alzheimer’s disease and dementias US20020094999A1 (2002).
   Google Scholar
• Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci U S A. 2005;102:17213–17218.
   PubMed Web of Science ®Google Scholar
• Greig NH, Yu Q, Luo W, et al. Racemic N1-Norphenserine and its enantiomers: unpredicted inhibition of human acetyl- and butyrylcholinesterase and β-amyloid precursor protein in vitro. Heterocycles. 2003;61:529-539.
   Web of Science ®Google Scholar
• Yu Q, Holloway HW, Utsuki T, et al. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer’s disease. J Med Chem. 1999;42:1855–1861.
   PubMed Web of Science ®Google Scholar
• Espacenet - Home page. Available from: https://worldwide.espacenet.com/. [Last access May, 5 2018]
   Google Scholar
• Homepage - Questel. Available from: https://www.questel.com/. [Last access May, 5 2018]
   Google Scholar
• China Drives International Patent Applications to Record Heights; Demand Rising for Trademark and Industrial Design Protection Available from: http://www.wipo.int/pressroom/en/articles/2018/article_0002.html. [Last access May, 4 2018]
   Google Scholar
• Sugimoto H, Takahashi J, Takahashi THI Indoline derivatives. US20110294850 (2010).
   Google Scholar
• Ellman GL, Courtney KD, Andres V, et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961;7:88–95.
   PubMed Web of Science ®Google Scholar
• University. MCKP of W. Novel hybrid cholinesterase inhibitors. WO2012165981A1 (2012).
   Google Scholar
• Floyd RA, Hensley K. Oxidative stress in brain aging: implications for therapeutics of neurodegenerative diseases. Neurobiol Aging. 2002;23:795–807.
   PubMed Web of Science ®Google Scholar
• Fernández-Bachiller MI, Pérez C, Campillo NE, et al. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer’s disease, with cholinergic, antioxidant, and neuroprotective properties. ChemMedChem. 2009;4:828–841.
   PubMed Web of Science ®Google Scholar
• Martinez Gil A, Dorronsoro Diaz I, Rubio Arrieta L, et al. Tacrine derivatives as inhibitors of acetylcholinesterase. WO2005/005413 (2005).
   Google Scholar
• Brus B, Košak U, Knez DCN Disubstituted piperidine derivatives as butyrylcholinesterase inhibitors for use in the treatment of Alzheimer. WO2016151484 (2016).
   Google Scholar
• Van Der Schyf CJ. The use of multi-target drugs in the treatment of neurodegenerative diseases. Expert Rev Clin Pharmacol. 2011;4:293–298.
   PubMedGoogle Scholar
• Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol. 2011;70:532–540.
   PubMed Web of Science ®Google Scholar
• Esteban G, Unzeta M, Inokuchi T, et al. Neuroprotective multi-target directed drugs. EP2727916A1 (2014).
   Google Scholar
• Riederer P, Danielczyk W, Grünblatt E. Monoamine oxidase-B inhibition in Alzheimer’s Disease. Neurotoxicology. 2004;25:271–277.
   PubMed Web of Science ®Google Scholar
• Mandel SA, Amit T, Kalfon L, et al. Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG). J. Alzheimers. 2008;15:211–222.
   PubMed Web of Science ®Google Scholar
• Fowler CJ, Tifton KF. Concentration dependence of the oxidation of tyramine by the two forms of rat liver mitochondrial monoamine oxidase. Biochem Pharmacol. 1981;30:3329–3332.
   PubMed Web of Science ®Google Scholar
• Li K, Reichmann H. Role of iron in neurodegenerative diseases. J Neural Transm. 2016;123:389–399.
   PubMed Web of Science ®Google Scholar
• Abd El-Gaber MK, Hassan HY, Mahfouz NM, et al. Synthesis, biological investigation and molecular docking study of N-malonyl-1,2-dihydroisoquinoline derivatives as brain specific and shelf-stable MAO inhibitors. Eur J Med Chem. 2015;93:481–491.
   PubMed Web of Science ®Google Scholar
• Zhipei S, Keren W, Wenmin L et al. Tetrahydroisoquinoline compound and preparation method and application thereof. CN106831714A (2017).
   Google Scholar
• Matsumoto T, Suzuki O, Furuta T, et al. A sensitive fluorometric assay for serum monoamine oxidase with kynuramine as substrate. Clin Biochem. 1985;18:126–129.
   PubMed Web of Science ®Google Scholar
• Lianquan G, Wen L, Jiaheng T et al. Tacrine heterocomplex, preparation method and use in medicines for curing neurodegenerative diseases thereof. CN102229602A (2011).
   Google Scholar
• LeVine H. [18] Quantification of β-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 1999;309:274–284.
   PubMed Web of Science ®Google Scholar
• Xixin H, Peicing L, Jiantao Y et al. Tacrine-caffeic acid hetero-blends, their preparation method and medicinal compositions. CN102617465 (2012).
   Google Scholar
• de los Ríos C. Cholinesterase inhibitors: a patent review (2007–2011). Expert Opin Ther Pat. 2012;22:853–869.
   PubMed Web of Science ®Google Scholar
• Kandiah N, Pai M-C, Senanarong V, et al. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and parkinson’s disease dementia. Clin Interv Aging. 2017;12:697–707.
   PubMed Web of Science ®Google Scholar
• Ailin L, Lili G, Guanhua D et al. Compound with dual restraining activities to acetyl cholinesterase and butyryl cholinesterase and use thereof. CN101311171B (2011).
   Google Scholar
• Schellhammer I, Rarey M. FlexX-Scan: fast, structure-based virtual screening. Proteins Struct Funct Bioinforma. 2004;57:504–517.
   PubMed Web of Science ®Google Scholar
• Jinyi X, Chaolei W, Jie L et al. Isochroman-4-ketone derivative having cholinesterase inhibiting activity and preparation method ad medical application thereof. CN105218529A (2016).
   Google Scholar
• Jin Jinhui YW, Kasmumu R, Huangjian Y et al. Medical application and preparation method of fructus terminaliae billericae pulp butyrylcholinesterase inhibitory activity extract and composition of fructus terminaliae billericae pulp butyrylcholinesterase inhibitory activity extract. CN104644704A (2015).
   Google Scholar
• Rhee IK, van de Meent M, Ingkaninan K, et al. Screening for acetylcholinesterase inhibitors from Amaryllidaceae using silica gel thin-layer chromatography in combination with bioactivity staining. J Chromatogr A. 2001;915:217–223.
   PubMed Web of Science ®Google Scholar
• Unlu S, Esiringu I, Sahin Y et al. 3-substituted-6h-benzo[c]chromen-6-ones and benzo[c] chromen-6-ones against senile dementia. WO2014129989A1 (2014).
   Google Scholar
• Changhong W, Xuemei C, Yutao W et al. Vasicine R-type optical isomer as well as preparation method and application thereof. CN104356138 (2015).
   Google Scholar
• Liu W, Wang Y, He D, et al. Antitussive, expectorant, and bronchodilating effects of quinazoline alkaloids (±)-vasicine, deoxyvasicine, and (±)-vasicinone from aerial parts of Peganum harmala L. Phytomedicine. 2015;22:1088–1095.
   PubMed Web of Science ®Google Scholar
• Chunlin L, Jifeng LYW Compound 1,10-N-decylene lycorine dibromo salt, pharmaceutical composition and application thereof in medicine. CN102746325B (2014).
   Google Scholar
• Cortes N, Posada-Duque RA, Alvarez R, et al. Neuroprotective activity and acetylcholinesterase inhibition of five Amaryllidaceae species: a comparative study. Life Sci. 2015;122:42–50.
   PubMed Web of Science ®Google Scholar
• Chambers JE, Chambers HW, Meek EC Novel oximes for reactivating butyrylcholinesterase. US20170258774 (2017).
   Google Scholar
• Elgorashi EE, Stafford GI, Van Staden J. Acetylcholinesterase enzyme inhibitory effects of amaryllidaceae alkaloids. Planta Med. 2004;70:260–262.
   PubMed Web of Science ®Google Scholar
• Chambers JE, Chambers HW, Meek EC, et al. Testing of novel brain-penetrating oxime reactivators of acetylcholinesterase inhibited by nerve agent surrogates. Chem Biol Interact. 2013;203:135–138.
   PubMed Web of Science ®Google Scholar
• Schneider LS, Mangialasche F, Andreasen N, et al. Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J Intern Med. 2014;275:251–283.
   PubMed Web of Science ®Google Scholar
• Cummings J, Lee G, Mortsdorf T, et al. Alzheimer’s disease drug development pipeline: 2017. Alzheimer’s Dement Transl Res Clin Interv. 2017;3:367–384.
   PubMedGoogle Scholar